StemRIM StemRIM

Investor Library

StemRIMIR LibraryTimely Disclosure Information
All Timely Disclosure Information Financial Results Presentation Materials IR News
June 17, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
June 16, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
June 10, 2026 Timely Disclosure Information
Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]
May 13, 2026 Timely Disclosure Information
StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock
May 12, 2026 Timely Disclosure Information
StemRIM Announces the Progress for Regeneration-Inducing Medicine Redasemtide
April 15, 2026 Timely Disclosure Information
StemRIM Announces Completion of Patient Enrollment in the Phase 1,2 Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy
March 13, 2026 Timely Disclosure Information
Presentation Material Financial Results for the Six Months Ended January 31, 2026
March 11, 2026 Timely Disclosure Information
Non-consolidated Financial Results for the Six Months Ended January 31, 2026 [Japanese GAAP]
March 2, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code: SR-GT1) Aimed at Curative Treatment of DEB
February 17, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Canada) for the Use of Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
December 25, 2025 Timely Disclosure Information
StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke
December 17, 2025 Timely Disclosure Information
StemRIM Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty L
December 10, 2025 Timely Disclosure Information
Non-consolidated Financial Results for the Three Months Ended October 31, 2025 [Japanese GAAP]
December 10, 2025 Timely Disclosure Information
StemRIM Announces the Formation of a Compensation Committee on a Voluntary Basis
December 10, 2025 Timely Disclosure Information
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation